{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:28:40Z","timestamp":1791584920947,"version":"4.3.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["ID RP240442"],"award-info":[{"award-number":["ID RP240442"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clgc.2025.102384","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:57:27Z","timestamp":1749898647000},"page":"102384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Outcomes of Patients With Metastatic Prostate Cancer With Microsatellite Instability Treated With Pembrolizumab"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3894-0784","authenticated-orcid":false,"given":"Nicholas","family":"Lambert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Klavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waddah","family":"Arafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6273-3144","authenticated-orcid":false,"given":"Kevin","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clgc.2025.102384_bib0001","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"issue":"17","key":"10.1016\/j.clgc.2025.102384_bib0002","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","article-title":"Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer","volume":"30","author":"Lenis","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2025.102384_bib0003","unstructured":"FDA. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication Accessed December 19, 2024."},{"issue":"9","key":"10.1016\/j.clgc.2025.102384_bib0004","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102384_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102384_bib0006","series-title":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer 1.2025 \u00a9 National Comprehensive Cancer Network, Inc","author":"Spratt","year":"2024"},{"issue":"8","key":"10.1016\/j.clgc.2025.102384_bib0007","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/oncolo\/oyae156","article-title":"Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation","volume":"29","author":"Moore","year":"2024","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.clgc.2025.102384_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001065","article-title":"Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA","volume":"8","author":"Barata","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2025.102384_bib0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2020.38.6_suppl.15","article-title":"Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5","volume":"38","author":"Graff","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.clgc.2025.102384_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114336","article-title":"Duration of immunotherapy in dMMR\/MSI-H metastatic colorectal cancer patients","volume":"212","author":"Margalit","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102384_bib0011","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41391-024-00799-y","article-title":"A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and\/or tumor mutation burden-high metastatic castration resistant prostate cancer: outcome analysis","volume":"28","author":"Mosalem","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.clgc.2025.102384_bib0012","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00262-021-02966-9","article-title":"PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients","volume":"71","author":"Wang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"10.1016\/j.clgc.2025.102384_bib0013","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"van Wilpe","year":"2024","journal-title":"Annal Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:39:59Z","timestamp":1778618399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1558767325000849"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102384","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes of Patients With Metastatic Prostate Cancer With Microsatellite Instability Treated With Pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102384"}}